Table 4.
Multivariate analysis of significant risk factors for survival
| P | Hazard | % 95 CI | |
|---|---|---|---|
| LRC | |||
| GP96 over-expression | 0.018 | 5.808 | 1.345-25.093 |
| DMFS | |||
| GP96 over-expression | 0.072 | 6.504 | 0.848-49.871 |
| Skin invasion | 0.020 | 4.973 | 1.289-19.190 |
| Differentiation | 0.015 | 3.975 | 1.309-12.065 |
| Concurrent chemotherapy | 0.052 | 3.276 | 0.992-10.821 |
| DFS | |||
| GP96 over-expression | 0.006 | 5.326 | 1.614-17.580 |
| Nodal ECS | 0.019 | 2.337 | 1.148-4.758 |
| DSS | |||
| GP96 over-expression | 0.011 | 6.532 | 1.530-27.890 |
| Nodal ECS | 0.014 | 2.698 | 1.225-5.942 |
| Skin invasion | 0.040 | 2.806 | 1.046-7.526 |
| OS | |||
| GP96 over-expression | 0.012 | 3.355 | 1.302-8.648 |
| Nodal ECS | 0.005 | 2.533 | 1.332-4.819 |
Abbreviation: LRC = locoregional control; DMFS = distant metastasis-free survival; DFS = disease-free survival; DSS = disease-specific survival; OS = overall-survival; ECS = extra-capsular spreading.